Findings

What do systematic reviews say?

670 questions · 686 findings · 338 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%

Cannabidiol vs placebo

IBDQ at week 6 · people with active UC

1 finding from 1 review

Cannabis for the treatment of ulcerative colitis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Moderate

Varenicline vs placebo

Generic quality of life measures · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Bisphosphonates vs placebo

Number of participants with change in quality of life measures (not measured) · Paget's disease of bone

1 finding from 1 review

Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Proparacaine hydrochloride 0.5% eye drops vs placebo

Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia

The review found no eligible studies for this question.

1 finding from 1 review

Non‐antiepileptic drugs for trigeminal neuralgia 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended‐release methylphenidate vs placebo

Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

1 finding from 1 review

Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1888 participants
Very low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Oral steroids vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Electromagnetic field treatment vs placebo

Quality of life SF‐36 item Scale from: 0 to 100 (Lower scores mean worse quality) · patients with osteoarthritis

1 finding from 1 review

Electromagnetic fields for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 145 participants
Moderate

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Quality of life: respiratory domain · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 884 participants
Moderate

Lactulose vs lactitol

Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis

The review found no eligible studies for this question.

1 finding from 1 review

Non‐absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Anticholinergic medication vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Anticholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Vitamin E vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Vitamin E for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Natural products vs placebo

Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for somatoform disorders in adults 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal corticosteroids vs placebo

Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis

1 finding from 1 review

Intranasal corticosteroids for non‐allergic rhinitis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies

Quality of life Assessed by LIS (scale from: 0 to 48, better indicated by a lower score) · adults with anxiety disorders

It is very uncertain whether DCS and cognitive and behavioural therapies changes quality of life Assessed by LIS (scale from: 0 to 48, better… compared with placebo and cognitive and behavioural therapies (very low certainty).

1 finding from 1 review

Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High